Royalty Pharma
RPRX
£27.91
Share price
0.57%
Change (1 day)
24.83%
Change (1 year)
Categories
Royalty Pharma (RPRX) - Total debt
Total debt on the balance sheet as of March 2025 : £5.70 Billion
According to Royalty Pharma's latest financial reports the company's total debt is £5.70 Billion. A company’s total debt is the sum of all current and non-current debts.
Royalty Pharma - Total debt on balance sheet (from 2019 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | £6.06 B | 25.96% |
| 2023-12-31 | £4.81 B | -18.13% |
| 2022-12-31 | £5.88 B | 11.89% |
| 2021-12-31 | £5.25 B | 23.19% |
| 2020-12-31 | £4.26 B | -10.3% |
| 2019-12-31 | £4.75 B | -7.37% |
| 2018-12-31 | £5.13 B |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 ANI Pharmaceuticals ANIP | £0.46 B | -91.82% | 🇺🇸 USA |
 Abbott Laboratories ABT | £9.91 B | 73.84% | 🇺🇸 USA |
 Eli Lilly LLY | £28.84 B | 405.63% | 🇺🇸 USA |